A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

Valentine M. Macaulay,Simon Lord,Syed Hussain,José Pablo Maroto,Robert Hugh Jones,Miguel Ángel Climent,Natalie Cook,Chia-Chi Lin,Shian-Shiang Wang,Diletta Bianchini,Mark Bailey,Laura Schlieker,Thomas Bogenrieder,Johann de Bono

DOI: https://doi.org/10.1038/s41416-023-02380-1

IF: 9.075

2023-08-04

British Journal of Cancer

Abstract:This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer (mCRPC).

oncology